Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Current Liabilities (2021 - 2026)

Centessa Pharmaceuticals has reported Total Current Liabilities over the past 5 years, most recently at $42.9 million for Q4 2025.

  • Quarterly Total Current Liabilities fell 25.97% to $42.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.9 million through Dec 2025, down 25.97% year-over-year, with the annual reading at $42.9 million for FY2025, 25.97% down from the prior year.
  • Total Current Liabilities was $42.9 million for Q4 2025 at Centessa Pharmaceuticals, up from $29.1 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $58.0 million in Q4 2024 and troughed at $24.2 million in Q1 2025.
  • The 5-year median for Total Current Liabilities is $29.7 million (2025), against an average of $33.2 million.
  • Year-over-year, Total Current Liabilities skyrocketed 55.61% in 2022 and then dropped 25.97% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $24.6 million in 2021, then surged by 55.61% to $38.3 million in 2022, then increased by 2.73% to $39.4 million in 2023, then skyrocketed by 47.26% to $58.0 million in 2024, then fell by 25.97% to $42.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Total Current Liabilities are $42.9 million (Q4 2025), $29.1 million (Q3 2025), and $29.7 million (Q2 2025).